Yu Xianzhe, Zhu Lingling, Liu Jiewei, Xie Ming, Chen Jiang, Li Jianguo
Gastrointestinal Department, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, People's Republic of China.
Lung Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Onco Targets Ther. 2020 Nov 13;13:11645-11658. doi: 10.2147/OTT.S271955. eCollection 2020.
Colorectal cancer (CRC) is the third most common malignant tumor in the world and the second leading cause of cancer-related deaths, with the liver as the most common site of distant metastasis. The prognosis of CRC with liver metastasis is poor, and most patients cannot undergo surgery. In addition, conventional antitumor approaches such as chemotherapy, radiotherapy, targeted therapy, and surgery result in unsatisfactory outcomes. In recent years, immunotherapy has shown good prospects in the treatment of assorted tumors by enhancing the host's antitumor immune function, and it may become a new effective treatment for liver metastasis of CRC. However, challenges remain in applying immunotherapy to CRC with liver metastasis. This review examines how the microenvironment and immunosuppressive landscape of the liver favor tumor progression. It also highlights the latest research advances in immunotherapy for colorectal liver metastasis and identifies immunotherapy as a treatment regimen with a promising future in clinical applications.
结直肠癌（CRC）是全球第三大常见恶性肿瘤，也是癌症相关死亡的第二大主要原因，肝脏是最常见的远处转移部位。发生肝转移的CRC预后较差，大多数患者无法接受手术。此外，化疗、放疗、靶向治疗和手术等传统抗肿瘤方法的效果并不理想。近年来，免疫疗法通过增强宿主的抗肿瘤免疫功能，在各类肿瘤治疗中显示出良好前景，可能成为CRC肝转移的一种新的有效治疗方法。然而，将免疫疗法应用于发生肝转移的CRC仍面临挑战。本文综述探讨了肝脏的微环境和免疫抑制格局如何促进肿瘤进展。还重点介绍了结直肠癌肝转移免疫治疗的最新研究进展，并确定免疫疗法是一种在临床应用中具有广阔前景的治疗方案。
